Cytarabine/daunorubicin liposomal

Drug Profile

Cytarabine/daunorubicin liposomal

Alternative Names: CPX-351; Cytarabine:daunorubicin - Celator; Cytarabine:daunorubicin liposome injection - Celator; Daunorubicin/cytarabine; NS 87; VYXEOS

Latest Information Update: 10 May 2017

Price : $50

At a glance

  • Originator Celator Pharmaceuticals
  • Developer Cardiff University; Celator Pharmaceuticals; Cincinnati Childrens Hospital Medical Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (USA); Stanford University; The Leukemia & Lymphoma Society; University of Texas M. D. Anderson Cancer Center
  • Class Anthracyclines; Antineoplastics; Arabinonucleosides; Cytostatic antibiotics; Daunorubicins; Nucleosides; Small molecules
  • Mechanism of Action Antimetabolites; DNA intercalators; DNA synthesis inhibitors; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Acute myeloid leukaemia
  • Phase III Myelodysplastic syndromes
  • Phase II Acute lymphoblastic leukaemia
  • Phase I Lymphoma

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia presented at the 108th annual meeting of the American Association for Cancer Research (AACR-2017)
  • 31 Mar 2017 Jazz Pharmaceuticals completes rolling submission of an NDA for cytarabine/daunorubicin liposomal for Acute myeloid leukaemia
  • 30 Mar 2017 Jazz Pharmaceuticals and Nippon Shinyaku agree to co-promote and co-develop cytarabine/daunorubicin liposomal in Japan for Acute myeloid leukaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top